Clinical cohort analysis revealed that high expression of CDCA7 is significantly linked to shortened overall survival in DLBCL patients, and its co-occurrence with MYC rearrangement indicates a poorer response to rituximab therapy. Here, CDCA7 is linked to diffuse large B-cell lymphoma.